Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03337100 · ClinicalTrials.gov registry record · NA
The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 7
- Enrollment target
NCT03337100: Completed NA study, sponsored by Kaiser Permanente.
NCT03337100 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 7 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03337100, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 7 participants
- Enrollment target
Study Summary
In the setting of naloxone standing orders, this study will assess if co-dispensing naloxone with opioids to patients prescribed chronic opioid therapy changes opioid risk behaviors, increases naloxone uptake, and increases knowledge about overdose and naloxone.
Primary Outcome
Among survey participants, risk behavior will be assessed using the Opioid-Related Behaviors in Treatment (ORBIT) scale. The ORBIT is a scale used to identify recent risk behavior among patients receiving chronic opioid therapy. Scores on the single scale range from 0-40, with lower values representing less risk behavior.
Interventions
- BEHAVIORAL Co-Dispensing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-11-27 |
| Est. Completion | 2022-09-30 |
| Phase | NA |
What the finished NCT03337100 record still lists
NCT03337100 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Co-Dispensing is the first listed.
NCT03337100 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03337100 about?
NCT03337100 is a clinical study titled "The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy". In the setting of naloxone standing orders, this study will assess if co-dispensing naloxone with opioids to patients prescribed chronic opioid therapy changes opioid risk behaviors, increases naloxone uptake, and increases knowledge about overdose and naloxone.
What is the current status of trial NCT03337100?
This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2017-11-27. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT03337100?
The interventions under investigation include: Co-Dispensing (BEHAVIORAL).
Who is sponsoring clinical trial NCT03337100?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03337100's enrollment target sits among peer trials
7 1982nd of 2000 higher than 18 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI